Literature DB >> 12210871

Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.

Andrew Siderowf1, Michael McDermott, Karl Kieburtz, Karen Blindauer, Sandra Plumb, Ira Shoulson.   

Abstract

Our objective was to assess the test-retest reliability of the Unified Parkinson's Disease Rating Scale (UPDRS). The UPDRS is the most widely used instrument for measuring severity of parkinsonian symptoms in clinical research and in practice. The validity and inter-rater reliability of this scale have been previously studied. We examined the test-retest (intrarater) reliability of the UPDRS and derived subscales. Four hundred patients with early-stage Parkinson's disease (PD) who were participating in a multicenter clinical trial were evaluated using the UPDRS on two separate occasions (screening and baseline visits) prior to receiving treatment. The same neurologist at each center rated the subjects at both examinations that were, on average, 14.6 +/- 7.6 days apart (range 3-36 days). Test-retest reliability was estimated using the intraclass correlation coefficient (ICC) for the total UPDRS score, the mental, ADL, and motor subscale scores, and other derived subscale scores. Weighted kappa statistics were calculated for individual UPDRS items. The ICCs for the UPDRS scores were as follows: total score, 0.92; mental, 0.74; ADL, 0.85; motor, 0.90. ICCs for derived symptom-based scales ranged from 0.69-0.88. Reliability of specific items was generally lower than for summary scales. Reliability was slightly better in patients for whom the testing interval was within 14 days. Based on conventional standards, the UPDRS scores were found to have excellent test-retest reliability in this sample of patients with early PD rated by academic movement disorder specialists. The findings are in agreement with previous reports on interrater reliability. Copyright 2002 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210871     DOI: 10.1002/mds.10011

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  56 in total

1.  Use of power assist wheels results in increased distance traveled compared with conventional manual wheeling.

Authors:  Charles E Levy; Matthew P Buman; John W Chow; Mark D Tillman; Kimberly A Fournier; Peter Giacobbi
Journal:  Am J Phys Med Rehabil       Date:  2010-08       Impact factor: 2.159

2.  Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.

Authors:  B Ravina; M Putt; A Siderowf; J T Farrar; M Gillespie; A Crawley; H H Fernandez; M M Trieschmann; S Reichwein; T Simuni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  Minority enrollment in Parkinson's disease clinical trials.

Authors:  Myra G Schneider; Christopher J Swearingen; Lisa M Shulman; Jian Ye; Mona Baumgarten; Barbara C Tilley
Journal:  Parkinsonism Relat Disord       Date:  2008-08-09       Impact factor: 4.891

4.  Influence of Striatal Dopamine, Cerebral Small Vessel Disease, and Other Risk Factors on Age-Related Parkinsonian Motor Signs.

Authors:  Caterina Rosano; Andrea L Metti; Andrea L Rosso; Stephanie Studenski; Nicolaas I Bohnen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-03-09       Impact factor: 6.053

5.  Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale.

Authors:  Sydney E Seidel; Barbara C Tilley; Peng Huang; Yuko Y Palesch; Kenneth J Bergmann; Christopher G Goetz; Christopher J Swearingen
Journal:  Parkinsonism Relat Disord       Date:  2011-10-21       Impact factor: 4.891

6.  Application of modified regression techniques to a quantitative assessment for the motor signs of Parkinson's disease.

Authors:  Bambi R Brewer; Sujata Pradhan; George Carvell; Anthony Delitto
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2009-10-30       Impact factor: 3.802

7.  Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Authors:  Bernard Ravina; Kenneth Marek; Shirley Eberly; David Oakes; Roger Kurlan; Alberto Ascherio; Flint Beal; James Beck; Emily Flagg; Wendy R Galpern; Jennifer Harman; Anthony E Lang; Michael Schwarzschild; Caroline Tanner; Ira Shoulson
Journal:  Mov Disord       Date:  2012-09-13       Impact factor: 10.338

8.  Activity parameters of subthalamic nucleus neurons selectively predict motor symptom severity in Parkinson's disease.

Authors:  Andrew Sharott; Alessandro Gulberti; Simone Zittel; Adam A Tudor Jones; Ulrich Fickel; Alexander Münchau; Johannes A Köppen; Christian Gerloff; Manfred Westphal; Carsten Buhmann; Wolfgang Hamel; Andreas K Engel; Christian K E Moll
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

9.  Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale.

Authors:  Sotirios A Parashos; Jordan Elm; James T Boyd; Kelvin L Chou; Lin Dai; Zoltan Mari; John C Morgan; Lewis Sudarsky; Catherine L Wielinski
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

10.  Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Authors:  Michael A Schwarzschild; Alberto Ascherio; M Flint Beal; Merit E Cudkowicz; Gary C Curhan; Joshua M Hare; D Craig Hooper; Karl D Kieburtz; Eric A Macklin; David Oakes; Alice Rudolph; Ira Shoulson; Marsha K Tennis; Alberto J Espay; Maureen Gartner; Albert Hung; Grace Bwala; Richard Lenehan; Elmyra Encarnacion; Melissa Ainslie; Richard Castillo; Daniel Togasaki; Gina Barles; Joseph H Friedman; Lisa Niles; Julie H Carter; Megan Murray; Christopher G Goetz; Jeana Jaglin; Anwar Ahmed; David S Russell; Candace Cotto; John L Goudreau; Doozie Russell; Sotirios Andreas Parashos; Patricia Ede; Marie H Saint-Hilaire; Cathi-Ann Thomas; Raymond James; Mark A Stacy; Julia Johnson; Lisa Gauger; J Antonelle de Marcaida; Sheila Thurlow; Stuart H Isaacson; Lisbeth Carvajal; Jayaraman Rao; Maureen Cook; Charlise Hope-Porche; Lauren McClurg; Daniela L Grasso; Robert Logan; Constance Orme; Tori Ross; Alicia F D Brocht; Radu Constantinescu; Saloni Sharma; Charles Venuto; Joseph Weber; Ken Eaton
Journal:  JAMA Neurol       Date:  2014-02       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.